Oncolytic vaccinia virus: a silver bullet?
- PMID: 21105770
- PMCID: PMC9491121
- DOI: 10.1586/erv.10.137
Oncolytic vaccinia virus: a silver bullet?
References
-
- Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13(Suppl. 1), 5–13 (2008). - PubMed
-
- Simmons O, Magee M, Nemunaitis J. Current vaccine updates for lung cancer. Expert Rev. Vaccines 9(3), 323–335 (2010). - PubMed
-
- Coley W. Late results of the treatment of inoperable sarcoma by the mixed toxins of Erysipelas and Bacillus prodigiosus. Am. J. Med. Sci. 131, 375–428 (1906).
-
- Newman W, Southam CM. Virus treatment in advanced cancer. A pathological study of fifty seven cases. Cancer 7(1), 106–118 (1954). - PubMed
-
- Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15(4), 651–659 (2007). - PubMed
Websites
-
- Provenge (sipuleucel-T) www.provenge.com
-
- Genelux C. Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors. ClinicalTrial.gov, April (2010). NCT00794131 http://clinicaltrials.gov/ct2/show/NCT00794131
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources